- Reaction score
- 892
Group Buy?!?https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5769981/
They even call it a potential male pattern baldness treatment
Group Buy?!?https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5769981/
They even call it a potential male pattern baldness treatment
Group Buy?!?
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5769981/
They even call it a potential male pattern baldness treatment
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5769981/
They even call it a potential male pattern baldness treatment
Only 36 subjects to be divided into 2 (or 3) groups? Come on, man! Hell, if they enrolled them ahead of schedule, they could have waited to see how many more they could get.
We can argue where you draw the line between statistical vs anecdotal but I agree that demonstrating results on 24 people would be remarkable enough to make psy for the treatment.
The line between statistical and anecdotal depends entirely on the quality of the treatment. A bigger increase in hair count will rule out coincidence with a smaller sample.
But it won't be very accurate in telling us what % of people respond to the treatment, nor, consequently, how effective the treatment is if some people have a weak response and some a strong one. (in the sense that with as few people as 24, they might randomly cluster in the lower or the higher end)
Yeah, just 5 more years boys !New histogen news:
SAN DIEGO, Sept. 10, 2020 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite the body’s natural process to repair and maintain healthy biological function, today announced completion of patient dosing for the week 6 treatment timepoint in its Phase 1b/2a clinical trial of HST-001, designed to assess the safety, tolerability and indicators of efficacy of HST-001 for the treatment of androgenic alopecia in men.
“We are pleased to have accomplished the second of three treatment timepoints in our HST-001 trial and we remain on track to announce top line data results in the fourth quarter of this year,” said Richard W. Pascoe, Histogen’s President and CEO. “HST-001, if approved, could be a first-in-class product given its potential to stimulate new long-lasting hair growth in contrast to existing therapies that focus on reducing hair loss.”
https://www.globenewswire.com/news-...-2a-Trial-for-Androgenic-Alopecia-in-Men.html
Sounds good, but it's histogen so....yeah